Gaush Meditech Ltd
高视医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT
INTRAOCULAR LENS IMPLANT SYSTEM OBTAINED MEDICAL DEVICE REGISTRATION CERTIFICATE

This announcement is made by Gaush Meditech Ltd (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that Gaush Teleon Ltd* (高視泰靚醫療科技有限公司) ("**Gaush Teleon**"), a wholly-owned subsidiary of the Company, has obtained the class II medical device registration certificate for its "intraocular lens implant system" from the Guangdong Provincial Medical Products Administration.

Chinese Guideline for Cataract Surgery in Adults (2023) indicates that cataract is the leading cause of blindness worldwide. In the backdrop of growing aging population, the incidence rate of cataract increases year by year. Statistics of Chinese Ophthalmological Society show that cataract records an incidence rate of 80% among the Chinese population aged 60 to 89 and over 90% in the group aged over 90. It is expected that by 2050, China will have more than 240,000,000 adults suffering cataract. All the current cataract surgery therapies generally require the application of intraocular lens implant system to infuse the eyes with intraocular lens to replace the unclear natural crystalline lens, thus recovering the eyesight of such patients.

Expert Consensus on Prevention and Control of High Myopia (2023) shows that myopia is a disease of high incidence worldwide, with current global prevalence rate of over 28.3%, which is expected to reach 49.8% by 2050, and high myopia will report increasing prevalence rate from the current level of 4.0% to 9.8% by then. According to Guidelines on Myopia Prevention and Control (2024), the treatment of myopia could be realized by phakic intraocular lens implantation, which also requires the application of intraocular lens implant system to infuse the eyes with phakic intraocular lens to achieve the purpose of correction.

The accredited intraocular lens implant system (Registration Certificate No.: Yue Xie Zhu Zhun 20242161490), independently developed by Gaush Teleon, can be applied in the process of intraocular lens implantation for cataract surgery and also in the implantation of phakic intraocular lens for myopia treatment. This product not only satisfies the application requirements of the Group's monofocal and multifocal intraocular lens, but also becomes available to other peers for appropriate application.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, November 13, 2024

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.

** For identification purpose only*